SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is experiencing intense volatility and downward pressure as investors react to a weak sales outlook, with the community actively debating whether the company's turnaround efforts are failing against mounting competition and structural brand decline. Discussion is polarized between those viewing current levels as a long-term value opportunity and those calling for further drops due to concerns over inventory, geopolitical headwinds, and a perceived loss of market relevance.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as investors weigh an upcoming earnings report against the backdrop of broader cannabis sector volatility, with community debate sharply divided between those betting on a potential post-earnings rally or short squeeze and those citing concerns over dilution and management performance.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's long-term potential in AI infrastructure against broader market pressure from geopolitical instability in the Middle East. While bulls highlight upcoming earnings and expectations for new hyperscaler lease agreements as catalysts for a rebound, the stock is facing heavy selling pressure that has the community divided between those aggressively buying the dip and those concerned about the lack of immediate upward momentum.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is currently the subject of intense debate among investors as they weigh the company's long-term potential in the voice AI sector against persistent bearish sentiment and recent downward price pressure. The community is actively tracking high short interest and institutional buying patterns, with many traders looking for a potential squeeze catalyst while others remain cautious due to ongoing macroeconomic and geopolitical volatility.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF (NASA) is generating intense buzz following its debut as a pure-play space economy fund featuring significant direct exposure to SpaceX. While some traders view the ETF as an accessible, high-volatility opportunity to gain exposure to private space assets, skeptics are actively debating the fund's low assets under management and the transparency of its underlying holdings.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are heavily debating the sustainability of the semiconductor sector's parabolic run, with many actively trading SOXS to hedge against potential instability and potential cooling in AI-related spending. The community remains divided, as some continue to build short positions expecting a correction, while others caution that the sector's resilience in the face of geopolitical tension makes it a dangerous 'widowmaker' for those betting against it.

BARK, Inc. is a dog-centric company, engaged in making products, services, and content for dogs. It operates through the Direct to Consumer and Commerce segments. The Direct to Consumer segment is composed of subscription-based products delivered on a monthly basis. The Commerce segment refers to the sale of BARK products in retail stores and other e-tailers. The company was founded by Matt M. Meeker, Henrik Werdelin, and Carly Strife in 2012 and is headquartered in New York, NY.

BARK Inc - Ordinary Shares - Class A

BARK Inc

BARK is seeing heightened activity as investors weigh the company's recent debt-free status and cost-cutting measures against the upcoming 1-for-20 reverse stock split intended to regain NYSE compliance. While some in the community view the split as a necessary survival step to attract institutional interest, others are skeptical, with active discussions focusing on the potential for volatility, short interest dynamics, and the contrast between current valuation and historical performance.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is trending following the announcement of a clinical development collaboration with Pfizer for the Phase 2 study of ORIC-533, alongside a strategic private placement financing. The community is actively discussing the potential for a short squeeze, citing high short interest and the validation provided by Pfizers direct investment in the company.

Perpetua Resources Corp. is an exploration and development stage company that engages in acquiring mining properties with the intention of exploring, evaluating and placing into production. Its principal business is the exploration, redevelopment, restoration and operation of the Stibnite Gold Project in Idaho, USA. The firm's mineral project is the Stibnite Gold Project, which contains mineral deposits and focuses to explore, evaluate and redevelop all of the deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project. The company was founded in the year 1899 and is headquartered in Donnelly, ID.

Perpetua Resources Corp.

Perpetua Resources is trending following the U.S. Export-Import Bank's decision to advance its $2.7 billion loan for the Stibnite Gold Project to a 25-day congressional notice period, marking a significant milestone before final approval. The community is actively discussing the project's potential to provide a critical domestic supply of antimony for defense and semiconductors, with many investors highlighting the stock's long-term value despite recent volatility.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors closely monitor the FDA's timeline for the sNDA filing of AXS-05 for Alzheimer's disease agitation. The community is actively discussing the stock's recent price action at all-time highs while awaiting formal notification regarding the agency's review status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research

BTIG Research restated a "buy" rating and issued a $10.00 price target on shares of Connect Biopharma in a research report on Tuesday...

Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses

Connect Biopharma (NASDAQ:CNTB) shared new clinical and preclinical updates on rademikibart, its IL-4 receptor alpha monoclonal antibody, highlighting preliminary top-line results from an intravenous...

Connect Biopharma (CNTB) Expected to Announce Earnings on Monday

Connect Biopharma (NASDAQ:CNTB) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-connect-biopharma-holdings-limited-american-depositary-shares-stock...

Connect Biopharma Touts Next-Gen Dupixent Rademikibart, Near-Term Asthma/COPD Readouts

Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart outlined the company's focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a next-generation DUPIXENT, during a...

Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference

Connect Biopharma (NASDAQ:CNTB) CEO Barry Quart told investors at Oppenheimer's 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it...

BML Capital Management LLC Sells 554,058 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB

BML Capital Management LLC cut its stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) by 30.4% during the third quarter, according to its most recent 13F filing...

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors  DelveInsight

Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with...

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are...

Equities Analysts Offer Predictions for CNTB FY2030 Earnings

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Connect Biopharma in a report...

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Receives Average Rating of "Moderate Buy" from Brokerages

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five brokerages that are currently covering the...

Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.

Connect Biopharma Holdings Ltd

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$2.62
Prev Close	$2.90
Open	$2.78
Dividend Yield	N/A
50-Day Moving Average	$2.68
Beta	0.71
Avg. Volume	90,363.20
PE Ratio	-9.26

52-Week High	$3.82
52-Week Low	$0.51
Market Capitalization	$162.12M
EPS (Annual)	N/A
Price to Book	2.64
Revenue Per Employee	N/A

CNTB
Connect Biopharma Holdings Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest CNTB News

CNTBConnect Biopharma Holdings Ltd - ADR